Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 14/20 | 0.61 |
| ▸ | TUBB4A | P04350 | 8/20 | 0.61 |
| ▸ | TUBB | P07437 | 8/20 | 0.61 |
| ▸ | TUBA3C | P0DPH7 | 8/20 | 0.61 |
| ▸ | TUBA1B | P68363 | 8/20 | 0.61 |
| ▸ | TUBA4A | P68366 | 8/20 | 0.61 |
| ▸ | TUBB4B | P68371 | 8/20 | 0.61 |
| ▸ | TUBB3 | Q13509 | 8/20 | 0.61 |
| ▸ | TUBB2A | Q13885 | 8/20 | 0.61 |
| ▸ | TUBB8 | Q3ZCM7 | 8/20 | 0.61 |
| ▸ | TUBA3E | Q6PEY2 | 8/20 | 0.61 |
| ▸ | TUBA1A | Q71U36 | 8/20 | 0.61 |
| ▸ | TUBA1C | Q9BQE3 | 8/20 | 0.61 |
| ▸ | TUBB6 | Q9BUF5 | 8/20 | 0.61 |
| ▸ | TUBB2B | Q9BVA1 | 8/20 | 0.61 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.61 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.61 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.61 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.61 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14175303 | 0.94 | TUBB1 (0.58) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL15610936 | 0.92 | TUBB1 (0.56) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Fosbretabulin SCHEMBL29374788 | 0.91 | TUBB1 (0.61) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Fosbretabulin SCHEMBL66079 | 0.91 | TUBB1 (0.61) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Fosbretabulin SCHEMBL29417596 | 0.91 | TUBB1 (0.61) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL13479815 | 0.90 | TUBB1 (0.60) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Fosbretabulin SCHEMBL3542758 | 0.90 | TUBB1 (0.60) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Fosbretabulin SCHEMBL9707816 | 0.90 | TUBB1 (0.60) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Fosbretabulin SCHEMBL9708418 | 0.90 | TUBB1 (0.60) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| Fosbretabulin SCHEMBL3179235 | 0.90 | TUBB1 (0.60) | TUBB1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE45907-E1 | Functionalized stilbene derivatives as improved vascular targeting agents | OXIGENE, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-RE45720-E1 | Functionalized stilbene derivatives as improved vascular targeting agents | OXIGENE, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20090012325-A1 | Methods for preparing phosphoric acids of combrestastatin and derivatives thereof | OXIGENE, INC. | 2009-01-08 | — | — | US | disclosed |
| US-20090012325-A1 | Methods for preparing phosphoric acids of combrestastatin and derivatives thereof | OXIGENE, INC. | 2009-01-08 | — | — | US | disclosed |
| WO-2008103415-A2 | METHODS OF PREPARING PHOSPHORIC ACIDS OF COMBRETASTATIN AND DERIVATIVES THEREOF | OXIGENE, INC. (US) | 2008-08-28 | — | — | WO | disclosed |
| US-7384925-B2 | 2' Hydroxy-3'-bromo-3,4,4',5-tetramethoxy-(Z)-stilbene; antimitotic agent; inhibits the assembly of tubulin into microtubules; anticarcinogenic: solid tumor cancers, neovascularization; tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and A-4 (extract from willow tree) | OXIGENE, INC. (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384925-B2 | 2' Hydroxy-3'-bromo-3,4,4',5-tetramethoxy-(Z)-stilbene; antimitotic agent; inhibits the assembly of tubulin into microtubules; anticarcinogenic: solid tumor cancers, neovascularization; tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and A-4 (extract from willow tree) | OXIGENE, INC. (US) | 2008-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012325-A1 | Methods for preparing phosphoric acids of combrestastatin and derivatives thereof | TYMP, ATIC, CA4 | TUBB1 2257/4885TUBB4A 590/4885TUBB 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.